Suppr超能文献

人慢性T淋巴细胞白血病的酶细胞化学异质性,通过对二肽基氨基肽酶IV(DAP IV;EC 3.4.14.4)的反应性得以证明。

Enzymecytochemical heterogeneity of human chronic T-lymphocytic leukemia as demonstrated by reactivity to dipeptidylaminopeptidase IV (DAP IV; EC 3.4.14.4).

作者信息

Feller A C, Parwaresch M R, Bartels H, Lennert K

出版信息

Leuk Res. 1982;6(6):801-8. doi: 10.1016/0145-2126(82)90062-5.

Abstract

The observation that the dipeptidylaminopeptidase IV (DAP IV; EC 3.4.14.4) occurs exclusively in T mu lymphocytes, stimulated the following study on cases of chronic lymphocytic leukemias. Thirty cases of human chronic lymphocytic leukemia were subjected to the DAP IV reaction in addition to the usually applied cytochemical and immunological tests (acid alpha-naphthyl acetate esterase, acid phosphatase, rosetting with sheep erythrocytes and surface Ig). DAP IV activity was measured directly in normal granulocytes, monocytes, B and T lymphocytes as well as in lymphocyte suspensions of leukemic cases. On a cytochemical level granulocytes, monocytes, B lymphocytes and all 24 cases of B-CLL were found to be DAP IV negative, though some of the latter showed positive reactions for AcE and AcP. From the six cases of T-CLL, five were positive to DAP IV cytochemically. No discrepancies were observed between cytochemical and biochemical results. It is concluded that DAP IV is a reliable and easy to perform marker for T mu lymphocytes and their neoplasias. The results have been interpreted as further evidence for a clonal nature of T-cell neoplasias.

摘要

二肽基氨基肽酶IV(DAP IV;EC 3.4.14.4)仅存在于Tμ淋巴细胞中的这一观察结果,激发了对慢性淋巴细胞白血病病例的以下研究。除了通常应用的细胞化学和免疫学检测(酸性α-萘乙酸酯酶、酸性磷酸酶、与绵羊红细胞的玫瑰花结形成以及表面免疫球蛋白)外,对30例人类慢性淋巴细胞白血病进行了DAP IV反应检测。直接在正常粒细胞、单核细胞、B和T淋巴细胞以及白血病病例的淋巴细胞悬液中测量DAP IV活性。在细胞化学水平上,发现粒细胞、单核细胞、B淋巴细胞以及所有24例B-CLL均为DAP IV阴性,尽管其中一些对AcE和AcP呈阳性反应。在6例T-CLL病例中,5例在细胞化学上对DAP IV呈阳性。细胞化学和生化结果之间未观察到差异。得出结论,DAP IV是Tμ淋巴细胞及其肿瘤的一种可靠且易于操作的标志物。这些结果被解释为T细胞肿瘤克隆性质的进一步证据。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验